| Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix CA Davison, SM Durbin, MR Thau, VR Zellmer, SE Chapman, J Diener, ... Cancer research 73 (12), 3704-3715, 2013 | 132 | 2013 |
| Financial toxicity in cancer care: origins, impact, and solutions HR Abrams, S Durbin, CX Huang, SF Johnson, RK Nayak, GJ Zahner, ... Translational behavioral medicine 11 (11), 2043-2054, 2021 | 89 | 2021 |
| Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells JA Mason, CA Davison-Versagli, AK Leliaert, DJ Pape, C McCallister, ... Cell Death & Differentiation 23 (8), 1271-1282, 2016 | 69 | 2016 |
| Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors LA Petrillo, A El‐Jawahri, RD Nipp, MRL Lichtenstein, SM Durbin, ... Cancer 126 (10), 2288-2295, 2020 | 64 | 2020 |
| Evaluation of three commercial SARS-CoV-2 serologic assays and their performance in two-test algorithms SE Turbett, M Anahtar, AS Dighe, W Garcia Beltran, T Miller, H Scott, ... Journal of clinical microbiology 59 (1), 10.1128/jcm. 01892-20, 2020 | 51 | 2020 |
| Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study ST Chen, GE Molina, JA Lo, S Durbin, JV Cohen, KL Reynolds, ... Journal of the American Academy of Dermatology 82 (4), 994-996, 2020 | 28 | 2020 |
| Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer L Zubiri, GE Molina, MJ Mooradian, J Cohen, SM Durbin, L Petrillo, ... Journal for immunotherapy of cancer 9 (9), 2021 | 25 | 2021 |
| Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018 GE Molina, L Zubiri, JV Cohen, SM Durbin, L Petrillo, IM Allen, ... The Oncologist 26 (6), 514-522, 2021 | 23 | 2021 |
| Clinical outcomes of patients with metastatic cancer receiving immune checkpoint inhibitors in the inpatient setting SM Durbin, L Zubiri, A Niemierko, A Bardia, RJ Sullivan, C McEwen, ... The Oncologist 26 (1), 49-55, 2021 | 20 | 2021 |
| Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: a tsunami is coming, but … KL Reynolds, JV Cohen, S Durbin, M Thomas, M Dougan, HS Martinson, ... Journal of Clinical Oncology 36 (5_suppl), 127-127, 2018 | 15 | 2018 |
| Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis SM Durbin, MJ Mooradian, FJ Fintelmann, L Zubiri, DF Chute, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 13 | 2020 |
| Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor–induced gastroenterocolitis LL Thompson, E Katznelson, DE Leet, SM Durbin, J Yoon, KL Reynolds, ... European Journal of Cancer 142, 143-146, 2021 | 7 | 2021 |
| Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis YR Badran, F Zou, SM Durbin, BE Dutra, H Abu-Sbeih, AS Thomas, ... Journal for immunotherapy of cancer 11 (6), 2023 | 6* | 2023 |
| Identifying early-phase clinical trial participants at risk for experiencing worse clinical outcomes DM Lundquist, R Jimenez, S Durbin, N Horick, M Healy, A Johnson, ... JCO Oncology Practice 19 (6), e829-e837, 2023 | 5 | 2023 |
| Multi-detector computed tomography (MDCT)–based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis N Pisuchpen, SM Durbin, MJ Mooradian, FJ Fintelmann, KL Reynolds, ... European Radiology 31 (12), 8868-8878, 2021 | 3 | 2021 |
| Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting. S Durbin, L Zubiri, A Niemierko, LA Petrillo, A Bardia, RJ Sullivan, ... Journal of Clinical Oncology 37 (15_suppl), 6634-6634, 2019 | 3 | 2019 |
| Time toxicity in early phase clinical trials (EP-CTs). S Durbin, D Lundquist, M Healy, K Lynch, V Bame, T Martin, A Johnson, ... Journal of Clinical Oncology 40 (28_suppl), 236-236, 2022 | 2 | 2022 |
| Flu vaccination rate of patients with severe immune-related adverse events. IM Allen, YR Murciano-Goroff, L Zubiri, Q Li, MS Hughes, M Velimirovic, ... Journal of Clinical Oncology 37 (15_suppl), e18234-e18234, 2019 | 2 | 2019 |
| Patient-reported hope, quality of life, symptom burden, coping, and financial toxicity in early-phase clinical trial participants. D Lundquist, A Pelletier, S Durbin, V Bame, V Turbini, K Lynch, A Johnson, ... Journal of Clinical Oncology 40 (28_suppl), 275-275, 2022 | 1 | 2022 |
| Time burden and logistical intensity of early-phase clinical trials (EP-CTs). S Durbin, D Lundquist, R Jimenez, M Healy, A Johnson, V Bame, T Martin, ... Journal of Clinical Oncology 39 (28_suppl), 84-84, 2021 | 1 | 2021 |
